Comparative Evaluation of GPBB and CK-MB in Early Diagnosis of Acute Myocardial Infarction in Diabetic and Non-Diabetic Patients

Year : 2025 | Volume : 16 | Issue : 02 | Page : 33 37
    By

    Atul Khajuria,

  • Gagandeep Singh,

  1. Director, Desh Bhagat University, Mandi Gobindgarh, Punjab, India
  2. Assistant Professor, Faculty of Allied Health Sciences, Desh Bhagat University, Mandi Gobindgarh, Punjab, India

Abstract

Background: Acute myocardial infarction (AMI) continues to be a leading cause of morbidity and death among people worldwide. To lower the risk of problems, early and precise diagnosis is essential, particularly for diabetes patients. The study investigates the diagnostic value of Glycogen Phosphorylase BB (GPBB), a potential early biomarker of myocardial necrosis, and compares it with CK-MB, a widely used cardiac marker, in AMI diagnosis. Inflammatory markers (hs-CRP, IL-6, TNF-α) and Complete Blood Count (CBC) profiles were also assessed to understand their role in AMI. Objective: To evaluate and compare the diagnostic potential of GPBB and CK-MB for early detection of AMI in both diabetic and non-diabetic patients. Methods: This observational study included 370 participants: 240 AMI patients (180 diabetic and 60 non-diabetic) and 130 healthy controls. Blood samples were collected at admission to measure GPBB, CK-MB, hs-CRP, IL-6, TNF-α, and CBC parameters. At various points after admission, GPBB and CK-MB were evaluated for sensitivity, specificity, area under the curve (AUC), positive predictive value (PPV), negative predictive value (NPV), and specificity. SPSS (version 20.0) was used for the statistical analysis, and a p-value of less than 0.05 was deemed statistically significant. Results: Significant differences in demographic and clinical parameters were found between AMI patients and controls, including elevated BMI, blood pressure, and biochemical markers in AMI patients, especially diabetics. CBC results showed altered hemoglobin, RBC, WBC, and platelet counts in AMI patients. Biochemical markers, including RBG, FBG, HbA1c, and lipid profiles, were significantly higher in diabetic AMI patients. Inflammatory markers (hs-CRP, IL-6, TNF-α) were elevated in AMI patients. GPBB demonstrated superior diagnostic performance compared to CK-MB, with the highest sensitivity (97%) and specificity (96%) at the 2nd hour post-admission, while CK-MB peaked at the 6th hour with 81.25% sensitivity and 64% specificity. Conclusion: GPBB shows excellent diagnostic potential, outperforming CK-MB in the early detection of AMI, particularly within the first two hours. The study also highlights the significant role of inflammatory markers and CBC in understanding the pathophysiology of AMI. These findings suggest that GPBB could be a valuable tool in the early diagnosis of AMI, especially for high-risk populations like diabetic patients.

Keywords: Acute Myocardial Infarction, Glycogen Phosphorylase BB, CK-MB, Inflammatory Markers, Diabetic Patients, Early Diagnosis.

[This article belongs to Research and Reviews: A Journal of Pharmaceutical Science ]

How to cite this article:
Atul Khajuria, Gagandeep Singh. Comparative Evaluation of GPBB and CK-MB in Early Diagnosis of Acute Myocardial Infarction in Diabetic and Non-Diabetic Patients. Research and Reviews: A Journal of Pharmaceutical Science. 2025; 16(02):33-37.
How to cite this URL:
Atul Khajuria, Gagandeep Singh. Comparative Evaluation of GPBB and CK-MB in Early Diagnosis of Acute Myocardial Infarction in Diabetic and Non-Diabetic Patients. Research and Reviews: A Journal of Pharmaceutical Science. 2025; 16(02):33-37. Available from: https://journals.stmjournals.com/rrjops/article=2025/view=213574


References

  1. Zhao, Y., Zhang, Y., & Li, X. (2022). Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction: A meta-analysis. Frontiers in Cardiovascular Medicine, 9, 810123 https://doi.org/10.1002/jcla.24368
  2.  Wang, Y., Liu, J., & Zhang, L. (2022). Meta-analysis of the relationship between interleukin-6 levels and prognosis in acute coronary syndrome. Frontiers in Cardiovascular Medicine, 9, 823123. https://doi.org/10.3389/fcvm.2022.823123
  3. Miller, A., & Thompson, P. (2023). Inflammation in acute myocardial infarction: The good, the bad, and the ugly. European Heart Journal, 45(2), 89–96. https://doi.org/10.1093/eurheartj/ehaa885
  4. Harrison, D., & Patel, R. (2023). Glycogen phosphorylase BB in myocardial infarction. Biochemical Pharmacology, 184, 114358. https://doi.org/10.1016/j.bcp.2020.114358
  5. Singh, M., & Gupta, A. (2024). Adverse outcomes associated with interleukin-6 in patients with heart failure. Circulation: Heart Failure, 17(5), e010051. https://doi.org/10.1161/CIRCHEARTFAILURE.122.010051
  6. Patel, S., & Shah, N. (2025). IL-6 and cardiovascular risk: A narrative review. Current Atherosclerosis Reports, 27(3), 1–9. https://doi.org/10.1007/s11883-024-01259-7
  7. Lippi G, Mattiuzzi C, Comelli I, Cervellin G. Glycogen phosphorylase isoenzyme BB in the diagnosis of acute myocardial infarction: a meta-analysis. Biochemia Medica. 2013 Feb 15;23(1):78-82.
  8. Li H, Cen K, Sun W, Feng B. Predictive value of blood interleukin-6 level in patients with acute coronary syndrome: A meta-analysis. Immunological Investigations. 2021 Nov 17;50(8):964-76.
  9. He W, Liu Y, Liu J, Feng J, Li J, Lin L. IL-6 and HMGB1 Levels for Predicting Major Adverse Vascular Events after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. InThe Heart Surgery Forum 2024 Aug 20 (Vol. 27, No. 8, pp. E960-E967).
  10. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circulation research. 2021 May 28;128(11):1728-46.
Regular Issue Subscription Original Research
Volume 16
Issue 02
Received 01/04/2025
Accepted 12/04/2025
Published 19/06/2025
Publication Time 79 Days
139


My IP

PlumX Metrics